l aspartic acid Search Results


orotidine  (MedChemExpress)
94
MedChemExpress orotidine
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Orotidine, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid/pmc12869216-106-29-30
Average 94 stars, based on 1 article reviews
orotidine - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
n boc l aspartic acid  (BOC Sciences)
92
BOC Sciences n boc l aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
N Boc L Aspartic Acid, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/N-Boc-L-Aspartic+acid/pmc08867780-32-40-40
Average 92 stars, based on 1 article reviews
n boc l aspartic acid - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
aspartic acid  (BOC Sciences)
90
BOC Sciences aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Aspartic Acid, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid/pmc03868485-432-5-3
Average 90 stars, based on 1 article reviews
aspartic acid - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
aspartate  (Revvity)
90
Revvity aspartate
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Aspartate, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/Aspartic+acid%2C+L/pmc08406222-179-38-39
Average 90 stars, based on 1 article reviews
aspartate - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
l aspartic acid  (Thermo Fisher)
94
Thermo Fisher l aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
L Aspartic Acid, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L(%2B)-Aspartic+acid%2C+98%2B%25/10__1007_slash_s10965___020___02339___3-61-16-32
Average 94 stars, based on 1 article reviews
l aspartic acid - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
aspartic acid  (MedChemExpress)
93
MedChemExpress aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Aspartic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid/pmc10938170-37-34-60
Average 93 stars, based on 1 article reviews
aspartic acid - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
aspartic acid  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Aspartic Acid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid/pm23812099-505-34-41
Average 92 stars, based on 1 article reviews
aspartic acid - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
cat sc 285170  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology cat sc 285170
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Cat Sc 285170, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/Boc-L-aspartic+acid+beta-benzyl+ester+chloromethylketone/bio_rxiv__2025__02__23__639785-257-16-13
Average 93 stars, based on 1 article reviews
cat sc 285170 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
sc 22839  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology sc 22839
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Sc 22839, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid+hemimagnesium+salt+dihydrate/pmc06545161-2-7-4
Average 91 stars, based on 1 article reviews
sc 22839 - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
aga substrate asp amc  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology aga substrate asp amc
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
Aga Substrate Asp Amc, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid+%CE%B2/pmc10059667-128-1-9
Average 96 stars, based on 1 article reviews
aga substrate asp amc - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
t boc l aspartic acid  (BOC Sciences)
92
BOC Sciences t boc l aspartic acid
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
T Boc L Aspartic Acid, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/Boc-L-aspartic+acid/pmc09501011-101-67-67
Average 92 stars, based on 1 article reviews
t boc l aspartic acid - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
l aspartic acid β hydroxamate  (MedChemExpress)
94
MedChemExpress l aspartic acid β hydroxamate
Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or <t>Orotidine</t> (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.
L Aspartic Acid β Hydroxamate, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/l+aspartic+acid/L-Aspartic+acid+%CE%B2-hydroxamate/pmc12875573-236-8-19
Average 94 stars, based on 1 article reviews
l aspartic acid β hydroxamate - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or Orotidine (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.

Journal: Journal of Advanced Research

Article Title: Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes

doi: 10.1016/j.jare.2025.05.016

Figure Lengend Snippet: Uridine antagonizes the antiviral potency of Antimycin A. (A-C) Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). (A) Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was determined using a two-tailed unpaired Student's t -test: ****p < 0.0001, ns = no significant difference. (B) eGFP fluorescent expression in infected cells at the same time point (hpi) was visualized. Representative images are shown. Scale bars, 300 µm. Magnification, ×10. (C) Western blot was performed to quantify infection using anti-BHV-1 serum. β-actin was used as a loading control. (D) Schematic of the pyrimidine biosynthesis pathway: The de novo pathway generates uridine triphosphate (UTP) from cellular L-glutamine, while the salvage pathway can support pyrimidine synthesis by recycling preexisting nucleotides from extracellular sources, such as uridine. (E-H) Effect of pyrimidine intermediates on Antimycin A treatment: MDBK cells were treated with Antimycin A along with 100 μM of L-Aspartic acid (E), L-Hydroorotic acid (F), Orotic acid (G), or Orotidine (H) at the time of BHV-1 infection (MOI = 0.5). Infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay. Statistical significance was assessed using a two-tailed unpaired Student's t -test: ****p < 0.0001.

Article Snippet: The specific compounds used in this study included Antimycin A (MS0070-10MG; Maokang Biotechnology), Ara-C (MCE, HY-13605), Uridine (MCE, HY-B1449), Orotate (MCE, HY-N8060A), Dihydroorotate (MCE, HY-N0157), Aspartic Acid (MCE, HY-N0666R), Orotidine (MCE, 113226), Ascorbic Acid (MCE, B0166R), and BQR (MCE, 108325).

Techniques: Infection, Luciferase, Two Tailed Test, Expressing, Western Blot, Control